SCHEMBL583634

SCHEMBL583634

CCOC(=O)C1(NC(=O)OC(C)(C)C)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
ALDH1A1 P00352 2/20 0.38
TSHR P16473 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
HTT P42858 1/20 0.38
GHSR Q92847 1/20 0.37
TLR2 O60603 1/20 0.35
TLR1 Q15399 1/20 0.35
MAPK1 P28482 1/20 0.35
CTSL P07711 2/20 0.35
CA1 P00915 2/20 0.34
CA7 P43166 2/20 0.34
CA12 O43570 1/20 0.34
CA14 Q9ULX7 1/20 0.34
APLNR P35414 1/20 0.34
PIK3CD O00329 1/20 0.33
PIK3C2B O00750 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1351011 0.94 LATS1 (0.37) KMT2AMEN1ALDH1A1TSHRCYP1A2
SCHEMBL2746842 0.90 GHSR (0.36) KMT2AMEN1ALDH1A1TSHRCYP1A2
SCHEMBL2781817 0.90 OPRM1 (0.42) KMT2AMEN1ALDH1A1TSHRCYP1A2
SCHEMBL28302110 0.88 KMT2A (0.39) KMT2AMEN1ALDH1A1TSHRCYP1A2
SCHEMBL19706901 0.88 GHSR (0.40) KMT2AMEN1ALDH1A1TSHRCYP1A2
SCHEMBL14476480 0.87 TDP1 (0.37) KMT2AMEN1GHSRTLR2TLR1
SCHEMBL21903173 0.85 TLR2 (0.35) KMT2AMEN1GHSRTLR2TLR1
SCHEMBL1818103 0.85 TLR2 (0.35) KMT2AMEN1GHSRTLR2TLR1
SCHEMBL15619133 0.85 TLR2 (0.35) KMT2AMEN1GHSRTLR2TLR1
SCHEMBL298008 0.84 KMT2A (0.38) KMT2AMEN1ALDH1A1TSHRCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130005730-A1 NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS MEDIVIR AB (SE) 2013-01-03 US claimed
EP-3710429-B1 MICROBIOCIDAL PICOLINAMIDE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2023-04-05 EP disclosed
US-20230010358-A1 Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein PRELUDE THERAPEUTICS, INCORPORATED 2023-01-12 US disclosed
US-20220409589-A1 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY GENZYME CORP (US) 2022-12-29 US disclosed
US-11291205-B2 Microbiocidal picolinamide derivatives SYNGENTA PARTICIPATIONS AG (CH) 2022-04-05 US disclosed
US-11130769-B2 Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein PRELUDE THERAPEUTICS, INCORPORATED (US) 2021-09-28 US disclosed
EP-3877390-A1 SPIRO-SULFONAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN Prelude Therapeutics, Incorporated (US) 2021-09-15 EP disclosed
US-20210227826-A1 Microbiocidal Picolinamide Derivatives SYNGENTA PARTICIPATIONS AG (CH) 2021-07-29 US disclosed
CN-113166173-A Spiro-sulfonamide derivatives as inhibitors of myeloid leukemia 1(MCL-1) protein 普莱鲁德疗法有限公司 2021-07-23 CN disclosed
US-20200345700-A1 LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF MEDSHINE DISCOVERY INC. (CN) 2020-11-05 US disclosed
US-20040019058-A1 Chemokine receptor binding heterocyclic compounds with enhanced efficacy ANORMED CORPORATION (CA) 2004-01-29 US disclosed
WO-2003099316-A1 HETEROCYCLICSULFONAMIDE HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-12-04 WO disclosed
US-20030220341-A1 Chemokine receptor binding heterocyclic compounds with enhanced efficacy ANORMED, INC. (CA) 2003-11-27 US disclosed
WO-2003055876-A1 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY ANORMED INC. (CA) 2003-07-10 WO disclosed
US-5476950-A Aminopyrrolidine compound DAIICHI SEIYAKU CO., LTD. (JP) 1995-12-19 US disclosed
US-5416222-A Chemical intermediates to prepare pyridinocarboxylic acid derivatives with high antimicrobial activity and excellent pharmacokinetics DAIICHI SEIYAKU CO., LTD. (JP) 1995-05-16 US disclosed
US-5380874-A Pyrrolidine carbamates DAIICHI SEIYAKU CO., LTD. (JP) 1995-01-10 US disclosed
EP-0207420-B1 PYRIDONECARBOXYLIC ACID DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1992-05-06 EP disclosed
US-5098912-A Bactericides for grampositive bacteria DAIICHI SEIYAKU CO., LTD. (JP) 1992-03-24 US disclosed
EP-0207420-A2 Pyridonecarboxylic acid derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1987-01-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11291205-B2 Microbiocidal picolinamide derivatives CASP2, CASP1, MSR1 KMT2A 3971/4885MEN1 4263/4885ALDH1A1 1666/4885
US-20130005730-A1 NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS REN, AGTR1, ACE KMT2A 4186/4885MEN1 2296/4885ALDH1A1 273/4885
US-11130769-B2 Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein MCL1, BCL2A1, BCL2L1 KMT2A 1574/4885MEN1 1087/4885ALDH1A1 475/4885
US-20030220341-A1 Chemokine receptor binding heterocyclic compounds with enhanced efficacy CCR5, CXCR4, CXCR3 KMT2A 3464/4885MEN1 3210/4885ALDH1A1 3305/4885
US-20210227826-A1 Microbiocidal Picolinamide Derivatives CASP2, CASP1, MSR1 KMT2A 3971/4885MEN1 4263/4885ALDH1A1 1666/4885
US-20220409589-A1 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY CCR5, CXCR4, CXCR3 KMT2A 3464/4885MEN1 3210/4885ALDH1A1 3305/4885
US-20040019058-A1 Chemokine receptor binding heterocyclic compounds with enhanced efficacy CCR5, CXCR4, CXCR3 KMT2A 3464/4885MEN1 3210/4885ALDH1A1 3305/4885
US-20200345700-A1 LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF KDM1B, KDM1A, KDM2A KMT2A 30/4885MEN1 2603/4885ALDH1A1 290/4885
US-20230010358-A1 Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein MCL1, BCL2A1, BCL2L1 KMT2A 1574/4885MEN1 1087/4885ALDH1A1 475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.